Philip Staber, MD, PhD

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University, Austria

N/A

Poster(s):

• 1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL

• 1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial